ENHANZE® drug delivery technology may enable and optimize subcutaneous (SC) drug delivery for appropriate co-administered therapeutics, which may improve patient experiences, 1,2 increase health system efficiencies, 3-5 and optimize brand revenue.6

We currently have collaboration agreements for the ENHANZE drug delivery technology with Roche, Pfizer, Janssen, Baxalta, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion and argenx.

Marketed Products and Pipeline

rHuPH20 (ENHANZE drug delivery technology) is approved, sold, and/or reimbursed in 50+ countries as part of:

  • RITUXAN HYCELA®
  • MABTHERA® SC
  • HYQVIA®
  • HERCEPTIN® SC
  • HERCEPTIN HYLECTATM

Our partners also have additional products in nonclinical and clinical development. View the product pipeline.

1. Pivot X, Gligorov J, Müller V, et al. Ann Oncol. 2014;25(10):1979-1987.
2. Rummel M, Kim TM, Aversa F, et al. Ann Oncol. 2017;28:836-842.
3. Pivot X, Gligorov J, Müller V, et al. Lancet Oncol. 2013;14:962-970.
4. DeCock E, Pivot X, Hauser N, et al. Cancer Medicine. 2016;5(3):389-397.
5. Burcombe R, Chan S, Simcock R, et al. Adv Breast Cancer Res. 2013;2:133-140.
6. Walzer S, Era S, Profico A, Canciani M, Farina M, Ponzetti C. Poster presented at: ISPOR 18th Annual European Congress; 2015; Milan, Italy.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok